Relief Therapeutics Holding SA has published a joint presentation deck ahead of its business combination with NeuroX Group SA, expected to close in mid-December 2025. The company forecasts revenue of over 40 million Swiss Franc in 2027, growing to exceed 200 million Swiss Franc in 2031. Additionally, Relief Therapeutics anticipates achieving a normative EBITDA margin of around 55% by 2028, supported by the integration of NeuroX’s digital neurotherapeutics suite. The company’s stock is currently trading 5.66% higher at CHF 2.7050 on the Swiss Stock Exchange.

Read more at Nasdaq: Relief Therapeutics Publishes Joint Deck Ahead Of NeuroX Merger; Stock Up